Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01473940 | Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | completed | Phase 1 | 21 | Northwestern UniversityOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT00836407 | Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer | completed | Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 24, 2020 |
| clinicaltrials |
| NCT00439179 | A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema(BrUOG-PA205) | completed | Phase 1 | 27 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01744353 | BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study(278) | completed | Phase 1 | 35 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02559674 | QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | completed | Phase 1 | 8 | Altor BioScienceINDUSTRY | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03307148 | Stromal TARgeting for PAncreatic Cancer (STAR_PAC)(STAR_PAC) | completed | Phase 1 | 29 | Barts & The London NHS TrustOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02358161 | Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(MATRIX) | completed | Phase 1 / Phase 2 | 78 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT01488513 | ABC294640 in Treating Patients With Advanced Solid Tumors(ABC-101) | completed | Phase 1 | 22 | RedHill Biopharma LimitedINDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02541370 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 | completed | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03114631 | Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer | completed | Phase 1 / Phase 2 | 30 | The Republican Research and Practical Center for Epidemiology and MicrobiologyOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00634751 | CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma | completed | Phase 1 / Phase 2 | 48 | University of Wisconsin, MadisonOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT00398086 | Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 67 | CelgeneINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00005858 | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer | completed | Phase 1 | 25 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00379639 | A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors | completed | Phase 1 | 36 | CelgeneINDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02620800 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer(FABLOx) | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02148549 | Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study(FIRINOX) | completed | Phase 1 | 10 | Wakayama Medical UniversityOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02574663 | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | completed | Phase 1 | 66 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02338752 | Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02718859 | Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02894944 | Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer(Theragene) | completed | Phase 1 | 9 | Seoul National University HospitalOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03008304 | High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02583477 | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 1 / Phase 2 | 23 | AstraZenecaINDUSTRY | 2 | Aug 14, 2019 | clinicaltrials |
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT01858883 | Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 55 | Incyte CorporationINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02283372 | Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Washington University School of MedicineOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01893801 | Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | completed | Phase 1 / Phase 2 | 25 | Pancreatic Cancer Research TeamOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT01128296 | Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas | completed | Phase 1 / Phase 2 | 35 | Amer ZureikatOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT00923299 | Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine(THERAPY) | completed | Phase 1 / Phase 2 | 33 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01537107 | Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 31 | Mayo ClinicOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00711997 | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 9 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Mar 20, 2019 | clinicaltrials |
| NCT01984658 | A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients | completed | Phase 1 | 10 | CytoVac A/SINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00438256 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01286987 | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | completed | Phase 1 | 113 | PfizerINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01839981 | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 10 | Wake Forest University Health SciencesOTHER | 1 | Dec 27, 2018 | clinicaltrials |
| NCT01770132 | Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | completed | Phase 1 | 12 | John DeWittOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01833546 | A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 15, 2018 | clinicaltrials |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 8 | Theriva Biologics SLINDUSTRY | 1 | Oct 1, 2018 | clinicaltrials |
| NCT01663272 | A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 12 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02620423 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | completed | Phase 1 | 11 | Oncolytics BiotechINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2020source: clinicaltrials